Table 2.
Pharmacokinetic parameters of valsartan following intravenous injection of valsartan at a dose of 1 mg/kg in rats.
| Treatment | Valsartan + Rifampin | Valsartan + RGE | ||
|---|---|---|---|---|
| PK Parameters | Control | Rifampin | Control | RGE |
| T1/2 (h) | 4.48 ± 1.24 | 2.79 ± 0.32 * | 4.55 ± 0.98 | 4.59 ± 0.73 |
| C0 (ng/mL) | 1169.59 ± 118.78 | 1633.08 ± 1308.67 | 647.53 ± 50.49 | 781.47 ± 211.04 |
| AUC24h (ng·h/mL) | 667.56 ± 219.43 | 3318.65 ± 809.25 * | 859.36 ± 234.46 | 776.59 ± 228.82 |
| AUC∞ (ng·h/mL) | 681.03 ± 215.12 | 3325.83 ± 807.91 * | 881.62 ± 247.34 | 794.48 ± 226.13 |
| MRT (h) | 2.99 ± 0.47 | 3.37 ± 0.83 | 3.76 ± 1.16 | 3.81 ± 0.05 |
| CL (mL/min/kg) | 25.96 ± 6.30 | 15.55 ± 5.69 * | 20.03 ± 5.48 | 22.47 ± 7.12 |
| Vd (mL/kg) | 78.30 ± 25.66 | 55.03 ± 26.29 * | 72.16 ± 15.37 | 85.38 ± 25.82 |
Data represent mean ± SD of four rats per group. * p < 0.05 compared with control group. T1/2: elimination half-life; C0: initial plasma concentration at 1 h; AUC24h or AUC∞: Area under plasma concentration-time curve from zero to 24 h or infinity; MRT: mean residence time; CL: systemic clearance; Vd: Volume of distribution.